- Home
- Lung Transplant Therapeutics Market
Global Lung Transplant Therapeutics Market - Industry Trends and Forecast to 2029
- Published Date: January, 2022 | Report ID: CLS-48 | No of pages: 362 | Format:
The global lung transplant therapeutics market is projected to register a substantial CAGR of 4.8% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2021, and the forecast period is 2022 to 2029
Market Segmentation:
Global Lung Transplant Therapeutics Market, By Product (Immunosuppressant Drugs, Organ Preservation Products, Tissue Products, and Others), Indication (Chronic Obstructive Pulmonary Diseases (COPD), Pulmonary Fibrosis, Septic Lung Disease, Pulmonary Hypertension, Cystic Fibrosis, Interstitial Pulmonary Fibrosis, Emphysema, Sarcoidosis, Primary Pulmonary Arterial Hypertension, and Others), Type (Cadaveric Lung Transplantation, Living Lung Transplantation), Technique (Single-Lung Transplantation, Bilateral-Lung Transplantation, Heart-Lung Transplantation, and Double Lung Transplantation), Patient Demographics (Geriatric, Adult, Paediatric), End Users (Hospital, Transplant Centres, Specialty Centres, and Others), Country (U.S., Canada, Mexico, China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines and Rest of Asia-Pacific, Germany, Spain, France, Italy, U.K., Belgium, Netherlands, Switzerland, Russia, Turkey, Rest of Europe, Saudi Arabia, South Africa, Israel, U.A.E., Rest of Middle East and Africa) Industry Trends and Forecast to 2029
Some of the major factors contributing to the growth of the global lung transplant therapeutics market are:
Rising incidence of coronary obstructive pulmonary disorders
The rise in technological advancements
Market Players:
Some of the key market players in the global lung transplant therapeutics market are listed below:
Apotex Inc
Bridge to Life Ltd
TransMedics (A Subsidiary of TransMedics Group, Inc)
Intas Pharmaceuticals Ltd.
Viatris Inc.
BioLife Solutions
Paragonix Technologies, Inc
Ose-immuno
XVIVO
21st Century Medicine
Pfizer Inc.
F.Hoffmann-La Roche Ltd.
Panacea Biotec Ltd.
Astellas Pharma Inc.
Accord-UK Ltd
Novartis AG
Hikma Pharmaceuticals PLC
Dr. Franz Khler Chemie GmbH
Detraxi Inc
Dr. Reddys Laboratories Ltd.
TABLE OF CONTENT
TABLE OF CONTENTS
1 INTRODUCTION 44
1.1 OBJECTIVES OF THE STUDY 44
1.2 MARKET DEFINITION 44
1.3 OVERVIEW OF GLOBAL LUNG TRANSPLANT THERAPEUTICS MARKET 44
1.4 CURRENCY AND PRICING 45
1.5 LIMITATIONS 46
1.6 MARKETS COVERED 46
2 MARKET SEGMENTATION 50
2.1 MARKETS COVERED 50
2.2 GEOGRAPHICAL SCOPE 51
2.3 YEARS CONSIDERED FOR THE STUDY 52
2.4 DBMR TRIPOD DATA VALIDATION MODEL 53
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 56
2.6 MULTIVARIATE MODELLING 57
2.7 MARKET END USERS COVERAGE GRID 58
2.8 PRODUCT LIFELINE CURVE 59
2.9 DBMR MARKET POSITION GRID 60
2.10 VENDOR SHARE ANALYSIS 61
2.11 SECONDARY SOURCES 62
2.12 ASSUMPTIONS 62
3 EXECUTIVE SUMMARY 63
4 PREMIUM INSIGHTS 67
4.1 EPIDEMIOLOGY 69
4.2 PESTEL ANALYSIS 70
4.3 PORTERS FIVE FORCES MODEL 71
5 INSURANCE AND REIMBURSEMENT - GLOBAL LUNG TRANSPLANT THERAPEUTICS MARKET 72
5.1 U.S. 72
5.2 EUROPE 73
5.3 CANADA 73
5.4 INDIA 74
6 GLOBAL LUNG TRANSPLANT THERAPEUTICS MARKET: REGULATIONS 75
6.1 REGULATION IN THE U.S. 75
6.2 REGULATION IN EUROPE 76
6.3 REGULATION IN NEW ZEALAND 77
6.4 REGULATION IN AUSTRALIA 77
7 MARKET OVERVIEW 78
7.1 DRIVERS 80
7.1.1 INCREASE IN INCIDENCE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) 80
7.1.2 RISE IN AIR POLLUTION AND SURGE IN SMOKING 80
7.1.3 HIGH INCIDENCE OF CHRONIC DISEASES 81
7.1.4 RISE IN CLINICAL TRIALS 81
7.1.5 INCREASING DRUG APPROVALS 82
7.2 RESTRAINTS 82
7.2.1 LESS NUMBER OF DONORS FOR ORGAN DONATION 82
7.2.2 HIGH COST OF ORGAN TRANSPLANTATION 83
7.3 OPPORTUNITIES 83
7.3.1 RISING HEALTHCARE SPENDING 83
7.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS 84
7.3.3 TECHNOLOGICAL ADVANCEMENTS IN LUNG TRANSPLANTATION 84
7.4 CHALLENGES 85
7.4.1 STRINGENT REGULATORY FRAMEWORK 85
7.4.2 COMPLICATIONS ASSOCIATED WITH LUNG TRANSPLANTATION 85
8 IMPACT OF COVID-19 ON LUNG TRANSPLANT THERAPEUTICS MARKET 87
8.1 IMPACT ON PRICE 87
8.2 IMPACT ON DEMAND 87
8.3 IMPACT ON SUPPLY CHAIN 88
8.4 STRATEGIC INITIATIVES 88
8.5 CONCLUSION 88
9 GLOBAL LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT 89
9.1 OVERVIEW 90
9.2 IMMUNOSUPPRESSANT DRUGS 92
9.2.1 BY CLASS 93
9.2.1.1 CALCINEURIN INHIBITORS 94
9.2.1.1.1 TACROLIMUS 94
9.2.1.1.2 CYCLOSPORIN 94
9.2.1.2 ANTIMETABOLITE IMMUNOSUPPRESANTS 94
9.2.1.2.1 MYCOPHENOLATE MOFETIL 95
9.2.1.2.2 MYCOPHENOLATE SODIUM 95
9.2.1.2.3 AZATHIOPRINE 95
9.2.1.3 M-TOR INHIBITOR 95
9.2.1.3.1 SIROLIMUS 95
9.2.1.3.2 EVEROLIMUS 95
9.2.1.4 STEROIDS 95
9.2.1.4.1 METHYLPREDNISOLONE 96
9.2.1.4.2 PREDNISONE 96
9.2.1.5 MONOCLONAL ANTIBODY 96
9.2.1.5.1 BASILIXIMAB 96
9.2.1.5.2 MUROMONAB 96
9.2.1.6 OTHERS 97
9.2.2 BY DRUG TYPE 97
9.2.2.1 BRANDED 97
9.2.2.2 GENERIC 97
9.2.3 ROUTE OF ADMINISTRATION 97
9.2.3.1 ORAL ADMINISTRATION 97
9.2.3.2 PARENTERAL ADMINISTRATION 98
9.3 ORGAN PRESERVATION PRODUCTS 98
9.3.1 PERFADEX 99
9.3.2 HUMAN BIOSYSTEM (HBS) SOLUTION 99
9.3.3 LIFOR 99
9.3.4 CUSTODIOL HTK-(HISTIDINE-TRYPTOPHAN-KETOGLUTARATE) SOLUTION 99
9.3.5 RENOGRAF 99
9.3.6 OTHERS 99
9.4 TISSUE PRODUCT 100
9.5 OTHERS 100
10 GLOBAL LUNG TRANSPLANT THERAPEUTICS MARKET, BY TECHNIQUE 102
10.1 OVERVIEW 103
10.2 SINGLE-LUNG TRANSPLANT (SLT) 106
10.3 DOUBLE LUNG TRANSPLANT 106
10.4 BILATERAL LUNG TRANSPLANT (BLT) 107
10.5 HEART-LUNG TRANSPLANT 108
11 GLOBAL LUNG TRANSPLANT THERAPEUTICS MARKET, BY PATIENT DEMOGRAPHICS 109
11.1 OVERVIEW 110
11.2 ADULTS 113
11.3 GERIATRIC 114
11.4 PEDIATRIC 114
12 GLOBAL LUNG TRANSPLANT THERAPEUTICS MARKET, BY TYPE 116
12.1 OVERVIEW 117
12.2 CADAVERIC LUNG TRANSPLANT 119
12.3 LIVING LUNG TRANSPLANT 120
13 GLOBAL LUNG TRANSPLANT THERAPEUTICS MARKET, BY INDICATION 121
13.1 OVERVIEW 122
13.2 CYSTIC FIBROSIS 125
13.3 PULMONARY FIBROSIS 125
13.4 CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) 126
13.5 INTERSTITIAL PULMONARY FIBROSIS 127
13.6 PULMONARY HYPERTENSION 128
13.7 PRIMARY PULMONARY ARTERIAL HYPERTENSION 129
13.8 EMPHYSEMA 129
13.9 SARCOIDOSIS 130
13.10 SEPTIC LUNG DISEASE 131
13.11 OTHERS 132
14 GLOBAL LUNG TRANSPLANT THERAPEUTICS MARKET, BY END USER 133
14.1 OVERVIEW 134
14.2 HOSPITAL 137
14.3 TRANSPLANT CENTERS 137
14.4 SPECIALTY CENTERS 138
14.5 OTHERS 139
15 GLOBAL LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION 140
15.1 OVERVIEW 141
15.2 NORTH AMERICA 146
15.2.1 U.S. 155
15.2.2 CANADA 160
15.2.3 MEXICO 165
15.3 EUROPE 170
15.3.1 GERMANY 179
15.3.2 SPAIN 183
15.3.3 FRANCE 187
15.3.4 ITALY 191
15.3.5 U.K. 195
15.3.6 BELGIUM 199
15.3.7 NETHERLANDS 203
15.3.8 SWITZERLAND 207
15.3.9 RUSSIA 211
15.3.10 TURKEY 215
15.3.11 REST OF EUROPE 219
15.4 ASIA-PACIFIC 220
15.4.1 CHINA 229
15.4.2 INDIA 233
15.4.3 SOUTH KOREA 237
15.4.4 JAPAN 241
15.4.5 AUSTRALIA 245
15.4.6 THAILAND 249
15.4.7 MALAYSIA 253
15.4.8 PHILIPPINES 257
15.4.9 SINGAPORE 261
15.5 SOUTH AMERICA 274
15.5.1 BRAZIL 282
15.5.2 ARGENTINA 286
15.5.3 PERU 290
15.5.4 REST OF SOUTH AMERICA 294
15.6 MIDDLE EAST AND AFRICA 295
15.6.1 SAUDI ARABIA 303
15.6.2 SOUTH AFRICA 307
15.6.3 ISRAEL 311
15.6.4 UAE 315
15.6.5 REST OF MIDDLE EAST AND AFRICA 319
16 GLOBAL LUNG TRANSPLANT THERAPEUTICS MARKET: COMPANY LANDSCAPE 320
16.1 COMPANY SHARE ANALYSIS: GLOBAL 320
16.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 321
16.3 COMPANY SHARE ANALYSIS: EUROPE 322
16.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 323
17 SWOT ANALYSIS 324
18 COMPANY PROFILE 325
18.1 ASTELLAS PHARMA INC. 325
18.1.1 COMPANY SNAPSHOT 325
18.1.2 REVENUE ANALYSIS 325
18.1.3 COMPANY SHARE ANALYSIS 326
18.1.4 PRODUCT PORTFOLIO 326
18.1.5 RECENT DEVELOPMENT 326
18.2 TRANSMEDICS (A SUBSIDIARY OF TRANSMEDICS GROUP, INC) 327
18.2.1 COMPANY SNAPSHOT 327
18.2.2 REVENUE ANALYSIS 327
18.2.3 COMPANY SHARE ANALYSIS 328
18.2.4 PRODUCT PORTFOLIO 328
18.2.5 RECENT DEVELOPMENT 328
18.3 DR. REDDYS LABORATORIES LTD. 329
18.3.1 COMPANY SNAPSHOT 329
18.3.2 REVENUE ANALYSIS 329
18.3.3 COMPANY SHARE ANALYSIS 330
18.3.4 PRODUCT PORTFOLIO 330
18.3.5 RECENT DEVELOPMENT 330
18.4 F.HOFFMANN-LA ROCHE LTD. 331
18.4.1 COMPANY SNAPSHOT 331
18.4.2 REVENUE ANALYSIS 331
18.4.3 COMPANY SHARE ANALYSIS 332
18.4.4 PRODUCT PORTFOLIO 332
18.4.5 RECENT DEVELOPMENT 332
18.5 HIKMA PHARMACEUTICALS PLC 333
18.5.1 COMPANY SNAPSHOT 333
18.5.2 REVENUE ANALYSIS 333
18.5.3 COMPANY SHARE ANALYSIS 334
18.5.4 PRODUCT PORTFOLIO 334
18.5.5 RECENT DEVELOPMENT 334
18.6 APOTEX INC 335
18.6.1 COMPANY SNAPSHOT 335
18.6.2 PRODUCT PORTFOLIO 335
18.6.3 RECENT DEVELOPMENT 335
18.7 XVIVO 336
18.7.1 COMPANY SNAPSHOT 336
18.7.2 REVENUE ANALYSIS 336
18.7.3 PRODUCT PORTFOLIO 337
18.7.4 RECENT DEVELOPMENT 337
18.8 ACCORD-UK LTD 337
18.8.1 COMPANY SNAPSHOT 337
18.8.2 PRODUCT PORTFOLIO 338
18.8.3 RECENT DEVELOPMENT 338
18.9 BIOLIFE SOLUTIONS 339
18.9.1 COMPANY SNAPSHOT 339
18.9.2 REVENUE ANALYSIS 339
18.9.3 PRODUCT PORTFOLIO 340
18.9.4 RECENT DEVELOPMENT 340
18.10 BRIDGE TO LIFE LTD 341
18.10.1 COMPANY SNAPSHOT 341
18.10.2 PRODUCT PORTFOLIO 341
18.10.3 RECENT DEVELOPMENT 341
18.11 DETRAXI, INC. 342
18.11.1 COMPANY SNAPSHOT 342
18.11.2 PRODUCT PORTFOLIO 342
18.11.3 RECENT DEVELOPMENT 342
18.12 DR.FRANZ KOHLER CHEMIE GBMH 343
18.12.1 COMPANY SNAPSHOT 343
18.12.2 PRODUCT PORTFOLIO 343
18.12.3 RECENT DEVELOPMENT 343
18.13 INTAS PHARMACEUTICALS LTD. 344
18.13.1 COMPANY SNAPSHOT 344
18.13.2 PRODUCT PORTFOLIO 344
18.13.3 RECENT DEVELOPMENT 344
18.14 NOVARTIS AG 345
18.14.1 COMPANY SNAPSHOT 345
18.14.2 REVENUE ANALYSIS 345
18.14.3 PRODUCT PORTFOLIO 346
18.14.4 RECENT DEVELOPMENT 346
18.15 OSE-IMMUNO 347
18.15.1 COMPANY SNAPSHOT 347
18.15.2 PRODUCT PORTFOLIO 347
18.15.3 RECENT DEVELOPMENT 348
18.16 PANACEA BIOTEC LTD. 349
18.16.1 COMPANY SNAPSHOT 349
18.16.2 REVENUE ANALYSIS 349
18.16.3 PRODUCT PORTFOLIO 350
18.16.4 RECENT DEVELOPMENT 350
18.17 PARAGONIX TECHNOLOGIES, INC 351
18.17.1 COMPANY SNAPSHOT 351
18.17.2 PRODUCT PORTFOLIO 351
18.17.3 RECENT DEVELOPMENTS 351
18.17.3.1 PRODUCT LAUNCH 351
18.17.3.2 PARTNERSHIP 352
18.18 PFIZER INC. 353
18.18.1 COMPANY SNAPSHOT 353
18.18.2 REVENUE ANALYSIS 353
18.18.3 PRODUCT PORTFOLIO 354
18.18.4 RECENT DEVELOPMENT 354
18.19 VIATRIS, INC 355
18.19.1 COMPANY SNAPSHOT 355
18.19.2 REVENUE ANALYSIS 355
18.19.3 PRODUCT PORTFOLIO 356
18.19.4 RECENT DEVELOPMENT 356
18.20 21ST CENTURY MEDICINE 357
18.20.1 COMPANY SNAPSHOT 357
18.20.2 PRODUCT PORTFOLIO 357
18.20.3 RECENT DEVELOPMENT 357
19 QUESTIONNAIRE 358
20 RELATED REPORTS 362
Segmentation
Short Description:
Global Lung Transplant Therapeutics Market, By Product (Immunosuppressant Drugs, Organ Preservation Products, Tissue Products, and Others), Indication (Chronic Obstructive Pulmonary Diseases (COPD), Pulmonary Fibrosis, Septic Lung Disease, Pulmonary Hypertension, Cystic Fibrosis, Interstitial Pulmonary Fibrosis, Emphysema, Sarcoidosis, Primary Pulmonary Arterial Hypertension, and Others), Type (Cadaveric Lung Transplantation, Living Lung Transplantation), Technique (Single-Lung Transplantation, Bilateral-Lung Transplantation, Heart-Lung Transplantation, and Double Lung Transplantation), Patient Demographics (Geriatric, Adult, Paediatric), End Users (Hospital, Transplant Centres, Specialty Centres, and Others), Country (U.S., Canada, Mexico, China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines and Rest of Asia-Pacific, Germany, Spain, France, Italy, U.K., Belgium, Netherlands, Switzerland, Russia, Turkey, Rest of Europe, Saudi Arabia, South Africa, Israel, U.A.E., Rest of Middle East and Africa) Industry Trends and Forecast to 2029
Market Definition:
A lung transplant is surgery done to remove a diseased lung and replace it with a healthy lung from another person. Lung transplants surgery can be performed on people of almost all ages, from newborns to adults up to age 65 and sometimes even later. A lung transplant is for people who have tried other medications or treatments, but their underlying conditions have not improved sufficiently or worsened over time. Depending on the patient's medical condition, a lung transplant may involve replacing one lung or both. The lungs may be transplanted with a donor's heart in some situations. A lung transplant can significantly improve patient health and quality of life.
Market Segmentation:
The global lung transplant therapeutics market is categorized into six notable segments based on product, indication, type, technique, patient demographics, and end users.
On the basis of product, the global lung transplant therapeutics market is segmented into immunosuppressant drugs, organ preservation products, tissue products, and others
On the basis of indication, the global lung transplant therapeutics market is segmented into chronic obstructive pulmonary diseases (COPD), pulmonary fibrosis, septic lung disease, pulmonary hypertension, cystic fibrosis, interstitial pulmonary fibrosis, emphysema, sarcoidosis, primary pulmonary arterial hypertension, and others
On the basis of type, the global lung transplant therapeutics market is segmented into cadaveric lung transplantation, and living lung transplantation
On the basis of technique, the global lung transplant therapeutics market is segmented into single-lung transplantation, bilateral-lung transplantation, heart-lung transplantation, and double-lung transplantation
On the basis of patient demographics, the global lung transplant therapeutics market is segmented into geriatric, adult, pediatric
On the basis of end users, the global lung transplant therapeutics market is segmented into hospitals, transplant centers, specialty centers, and others
Market Players:
Some of the key market players in the global lung transplant therapeutics market are listed below:
Apotex Inc
Bridge to Life Ltd
TransMedics (A Subsidiary of TransMedics Group, Inc)
Intas Pharmaceuticals Ltd.
Viatris Inc.
BioLife Solutions
Paragonix Technologies, Inc
Ose-immuno
XVIVO
21st Century Medicine
Pfizer Inc.
F.Hoffmann-La Roche Ltd.
Panacea Biotec Ltd.
Astellas Pharma Inc.
Accord-UK Ltd
Novartis AG
Hikma Pharmaceuticals PLC
Dr. Franz Khler Chemie GmbH
Detraxi Inc
Dr. Reddys Laboratories Ltd.
Methodology
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
© 2025 Cognate Lifesciences. All Rights Reserved.